報價延遲最少15分鐘:2026/03/28 19:05 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.11/0.25
|
|
企業價值
931.46M
|
| 資產負債 |
|
每股賬面淨值
-1.18
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
403.14M
|
|
每股收益
0.43
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet. |
